Eric S Ciamporcero

List of Publications by Year
in descending order

38 papers	1,344 citations	393982 19 h-index	642321 23 g-index
39 all docs	39 docs citations	39 times ranked	2856 citing authors

#	Article	IF	Citations
1	Interaction of aldehydes derived from lipid peroxidation and membrane proteins. Frontiers in Physiology, 2013, 4, 242.	1.3	254
2	Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer. Oncotarget, 2013, 4, 2451-2461.	0.8	110
3	YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene, 2016, 35, 1541-1553.	2.6	108
4	Role of 4-Hydroxynonenal-Protein Adducts in Human Diseases. Antioxidants and Redox Signaling, 2015, 22, 1681-1702.	2.5	92
5	Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models. Molecular Cancer Therapeutics, 2015, 14, 101-110.	1.9	82
6	Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models. Cancer Immunology Research, 2015, 3, 136-148.	1.6	75
7	GSH-targeted nanosponges increase doxorubicin-induced toxicity â€œin vitroâ€•and â€œin vivoâ€•in cancer cells with high antioxidant defenses. Free Radical Biology and Medicine, 2016, 97, 24-37.	1.3	70
8	Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. European Journal of Pharmaceutical Sciences, 2012, 47, 686-694.	1.9	67
9	EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Research, 2017, 77, 6651-6666.	0.4	66
10	Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radical Biology and Medicine, 2018, 115, 447-457.	1.3	65
11	Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications. Molecular Cancer Therapeutics, 2015, 14, 513-522.	1.9	64
12	Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radical Biology and Medicine, 2011, 50, 313-322.	1.3	49
13	Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts. PLoS ONE, 2014, 9, e112371.	1.1	45
14	HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. BMC Cancer, 2016, 16, 617.	1.1	35
15	Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget, 2016, 7, 76374-76389.	0.8	32
16	Rosiglitazone and AS601245 Decrease Cell Adhesion and Migration through Modulation of Specific Gene Expression in Human Colon Cancer Cells. PLoS ONE, 2012, 7, e40149.	1.1	27
17	Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. Free Radical Biology and Medicine, 2011, 51, 1610-1618.	1.3	26
18	AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells. PPAR Research, 2012, 2012, 1-16.	1.1	22

#	Article	IF	Citations
19	PPARÎ³ in coronary atherosclerosis: In vivo expression pattern and correlations with hyperlipidemic status and statin treatment. Atherosclerosis, 2011, 218, 479-485.	0.4	19
20	The inclusion complex of 4-hydroxynonenal with a polymeric derivative of Î²-cyclodextrin enhances the antitumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model. Free Radical Biology and Medicine, 2013, 65, 765-777.	1.3	14
21	Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 147-156.	1.9	10
22	Improved Anti-Tumoral Therapeutic Efficacy of 4-Hydroxynonenal Incorporated in Novel Lipid Nanocapsules in 2D and 3D Models. Journal of Biomedical Nanotechnology, 2015, 11, 2169-2185.	0.5	8
23	Abstract 3508: Inhibition of EZH2 overcomes resistance to sunitinib in clear cell renal cell carcinoma models. , 2015, , .		1
24	Abstract 4061: Evidence for hdac6 and er-Î± association in a subset of clear cell renal cell carcinoma. , 2014, , .		1
25	Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. International Journal of Molecular Sciences, 2022, 23, 5770.	1.8	1
26	Abstract 4859: Tumor growth inhibition and epigenetic changes following protein diet restriction in a human prostate cancer model.. , 2013, , .		0
27	Abstract 686: Regulation of intracellular sequestration of sunitinib by cystine transporter xCT in renal cancer. , 2014, , .		0
28	Abstract 1375: Epigenetic changes associated with resistance to sunitinib in human clear cell renal cell carcinoma models. , 2014, , .		0
29	Abstract 1013: Angiopoietin 1/2 inhibition impairs tumor growth in an orthotopic model of renal cell carcinoma. , 2014, , .		0
30	Abstract 4132: Anti-tumor and anti-metastatic effect of sunitinib in a patient derived metastatic clear cell renal cell carcinoma xenograft model. , 2015, , .		0
31	Abstract 4110: Inhibition of angiopoietin 1/2 and c-MET impairs metastatic potential in a patient derived xenograft of renal carcinoma. , 2015, , .		0
32	Abstract 2546: HDAC and Hsp90 inhibition as therapeutic strategy for translocation renal cell carcinoma. , 2015, , .		0
33	Abstract 2514: Activity of a novel Foxp3-tumor cell vaccine in a murine model of renal cell carcinoma. , 2015, , .		0
34	Abstract 4300: Solute carrier family group of membrane transporter gene alteration in collecting duct renal cell carcinoma. , 2015, , .		0
35	Abstract 4120: Tasquinimod inhibits local invasion and metastases in two preclinical models of renal cell carcinoma. , 2015, , .		0
36	Abstract 1462: Characterization of patient-derived bladder cancer xenografts: role of xCT in response to cisplatin. , 2015, , .		0

#	Article	IF	Citations
37	Abstract 384: Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts. , 2016, , .		0
38	Abstract 897: Methionine restriction alters functional polarization of macrophages in a murine model of prostate cancer. , 2016, , .		0